Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Neurocrine Biosciences Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.21 (market cap $17.89B), while Neurocrine Biosciences Inc trades at $141.48 (market cap $14.36B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HYG | NBIX | |
|---|---|---|
Market Cap | $17.89B | $14.36B |
Volume | 44,866,592 | 1,237,180 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $185.50 |
52-Week Low | $76.90 | $123.10 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces pressure from rising Treasury yields impacting high-yield bond valuations. Recent dividend payments of $0.34-$0.44 provide income support amid market volatility.
The outlook remains challenged by persistent bond market selloffs and higher interest rates, though the current yield environment may attract income-seeking investors. Key risks include further Fed tightening and economic slowdown impacting corporate credit quality.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
